Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

By Nikhil Sharma (Reuters) -European shares dipped on Wednesday, as the rise in healthcare companies after Novo Nordisk's ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

Learn how GSK is harnessing the power of technology to improve outcomes for people with cancer.